12-Week Supervised Exercise Protocol Mitigates Hormone Therapy Side Effects in Prostate Cancer Trial

The moment a prostate cancer patient begins androgen deprivation therapy (ADT)—a systemic treatment utilized by up to 50 percent of men diagnosed with the disease—the clinical focus shifts from the tumor to the body's rapid loss of testosterone. This hormonal suppression starves the cancer cells, but it also triggers a cascade of secondary side effects. Up to 80 percent of patients experience profound fatigue, alongside accelerated muscle wasting and cardiovascular strain, which dictate whether a man can actually tolerate a regimen that often lasts 18 to 36 months. Mitigating that physical decline is the central challenge of prostate cancer management, and a new multicenter trial indicates that the most effective intervention is a highly specific, supervised exercise protocol.[1][5]

The STAMINA (Supported Exercise Training for Men with Prostate Cancer on Androgen Deprivation Therapy) trial, funded by the National Institute for Health and Care Research (NIHR) and led by researchers at Sheffield Hallam University, tested whether integrating a structured fitness program into standard care could offset these toxicities. Published in 2026, the study enrolled men undergoing hormone therapy across multiple UK National Health Service (NHS) trusts, including Sheffield Teaching Hospitals.[2][3][4]

Rather than simply advising patients to stay active, the STAMINA protocol prescribed a 12-week supervised exercise regimen. Participants engaged in tailored aerobic and resistance training sessions, guided by clinical exercise physiologists who adjusted the load and intensity based on individual fatigue levels and baseline fitness.[1][2]

The data showed a distinct divergence between the exercise group and those receiving standard care. Men in the supervised program reported significantly lower levels of treatment-induced fatigue and maintained higher scores on prostate cancer-specific quality-of-life assessments. According to the official clinical update from Sheffield Teaching Hospital, the structured fitness program directly "protects men from side effects of treatment," providing a proven buffer against the therapy's physical toll.[4]

The physiological mechanism behind this protection is rooted in mechanical loading. ADT strips the body of the anabolic hormones required to maintain muscle mass and bone density, with patients routinely losing 2 to 4 percent of their bone mineral density within the first 12 months of treatment. By introducing progressive mechanical overload through resistance training, the STAMINA protocol forces the neuromuscular system to preserve tissue that the hormonal environment is actively trying to break down.[1][5]

Simultaneously, the aerobic component of the 12-week program addresses the cardiovascular risks associated with ADT. Hormone therapy routinely alters lipid profiles and reduces insulin sensitivity, elevating the risk of metabolic syndrome. The supervised cardiovascular work in the trial helped stabilize these metabolic markers, offering a protective effect against the secondary risks of the cancer treatment.[3][5]

The challenge with exercise oncology is rarely the physiology; it is the implementation. The STAMINA trial specifically evaluated how to embed this intervention within the existing NHS infrastructure. By utilizing community leisure centers and training existing fitness staff to handle the specific clinical needs of oncology patients, the researchers demonstrated a scalable model that does not require building new hospital-based rehabilitation facilities.[2][3]

Adherence rates in the trial were notably high, a metric often difficult to achieve in populations experiencing severe clinical fatigue. The supervised nature of the program proved critical here. Having a trained professional monitor the sessions meant that on days when a patient's fatigue peaked, the workout was modified rather than skipped entirely, maintaining the habit without overtaxing the recovering system.[1][4]

The findings from the 2026 STAMINA trial provide a clear blueprint for updating clinical guidelines. As oncology departments review the data, the next operational hurdle is securing the funding to make supervised exercise a standard prescription alongside the hormone therapy itself, ensuring that preserving a patient's physical function is treated with the same urgency as suppressing the disease.[3][5]